Spots Global Cancer Trial Database for refractory hairy cell leukemia

Every month we try and update this database with for refractory hairy cell leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia	NCT00021983	Leukemia	BL22 immunotoxi...	18 Years -	National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia	NCT00021983	Leukemia	BL22 immunotoxi...	18 Years -	National Cancer Institute (NCI)
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia	NCT00005619	Leukemia	polymerase chai... flow cytometry immunohistochem...	18 Years -	Northwestern University
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	NCT02281279	B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	rituximab lenalidomide romidepsin laboratory biom...	18 Years -	Mayo Clinic
PS-341 in Treating Patients With Advanced Cancer	NCT00006362	Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu...	bortezomib	18 Years -	Mayo Clinic
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia	NCT00019838	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia	NCT00074048	Leukemia	BL22	18 Years -	MedImmune LLC
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy	NCT00003757	Leukemia	rituximab	18 Years -	Swiss Group for Clinical Cancer Research
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia	NCT00019838	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	NCT02037256	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	bortezomib filgrastim autologous hema...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy	NCT00003757	Leukemia	rituximab	18 Years -	Swiss Group for Clinical Cancer Research
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	NCT02109224	Adult B Acute L... Chronic Lymphoc... Cutaneous B-Cel... Extranodal Marg... HIV Infection Intraocular Lym... Multicentric An... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Refractory Hair... Refractory Plas... Small Intestina... Splenic Margina... Testicular Lymp... Waldenstrom Mac...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Sunitinib in Treating Patients With Idiopathic Myelofibrosis	NCT00387426	Accelerated Pha... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Mast Cell Leuke... Meningeal Chron... Primary Myelofi... Progressive Hai... Prolymphocytic ... Recurrent Adult... Recurrent Adult... Refractory Chro... Refractory Hair... Relapsing Chron... Secondary Acute... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... T-cell Large Gr... Untreated Adult... Untreated Adult... Untreated Hairy...	sunitinib malat...	18 Years -	National Cancer Institute (NCI)
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma	NCT00089076	Adult Grade III... B-cell Chronic ... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	ipilimumab laboratory biom...	18 Years -	National Cancer Institute (NCI)
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	NCT04578600	Indolent B-Cell... Recurrent B-Cel... Recurrent Chron... Recurrent Mucos... Recurrent Folli... Recurrent Hairy... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Chro... Refractory Muco... Refractory Foll... Refractory Hair... Refractory Lymp... Refractory Mant... Refractory Marg... Recurrent Small... Refractory Smal...	Lenalidomide Obinutuzumab Oral Azacitidin...	18 Years -	University of California, Davis
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	NCT00058227	B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Refractory Hair... Splenic Margina... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	alvocidib fludarabine pho... rituximab pharmacological...	18 Years -	National Cancer Institute (NCI)
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia	NCT00019838	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: